Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo

  title={Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo},
  author={S. Ranganath and A. Bhandari and Nicole Avitahl-Curtis and Jaimee McMahon and D. Wachtel and J. Zhang and C. Leitheiser and S. Bernier and G. Liu and T. T. Tran and Herodion Celino and Jenny V. Tobin and Joon Jung and Hong Zhao and K. Glen and Chris Graul and A. Griffin and W. Schairer and Carolyn S. Higgins and Tammi L. Reza and Eva Mowe and Sam Rivers and Sonya M. Scott and A. Monreal and C. Shea and Greg T. Bourne and C. Coons and A. Smith and Kim Tang and R. A. Mandyam and J. Masferrer and D. Liu and D. Patel and Angelika Fretzen and C. Murphy and G. T. Milne and M. Smythe and K. Carlson},
  journal={PLoS ONE},
  • S. Ranganath, A. Bhandari, +35 authors K. Carlson
  • Published 2015
  • Biology, Medicine
  • PLoS ONE
  • Interleukin-6 (IL-6) is an important member of the cytokine superfamily, exerting pleiotropic actions on many physiological processes. Over-production of IL-6 is a hallmark of immune-mediated inflammatory diseases such as Castleman’s Disease (CD) and rheumatoid arthritis (RA). Antagonism of the interleukin IL-6/IL-6 receptor (IL-6R)/gp130 signaling complex continues to show promise as a therapeutic target. Monoclonal antibodies (mAbs) directed against components of this complex have been… CONTINUE READING
    26 Citations
    Interleukin-6: a molecule with complex biological impact in cancer.
    • 12
    IL‑6/STAT3/miR‑34a protects against neonatal lung injury patients.
    • 3
    • PDF
    Clustering of disulfide-rich peptides provides scaffolds for hit discovery by phage display: application to interleukin-23
    • 7
    Oral Delivery of Biologics for Precision Medicine.
    • 18
    Miniproteins as a Powerful Modality in Drug Development.
    • 5
    The establishment of a rheumatoid arthritis primate model in Macaca fascicularis


    Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities.
    • 205
    Interleukin 6: from bench to bedside
    • 363
    Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases
    • 163
    • PDF
    Principles of interleukin (IL)-6-type cytokine signalling and its regulation.
    • 2,776
    • PDF
    Effect of immunosuppressive agents FK506 and cyclosporin and steroids on the expression of IL‐6 and its receptor by stimulated lymphocytes and monocytes
    • 6
    Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.
    • 188
    Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance.
    • 285
    Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin
    • 1,920
    CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice
    • 101